ImmunityBio, Inc. (IBRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.08-1.34%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
ImmunityBio grew revenue from $7.55M to $44.2M in 2026-Q1. FDA approved a key product in May 2026. The company formed a strategic deal with Japan BCG Laboratory. These steps support future sales growth and market reach.
The company lost $69.79M in 2026-Q1, worsening from prior quarters. Analysts expect revenue to fall about 60% next year. Managing costs remains a challenge with no clear improvement.
The market expects about 60% revenue decline next year. Our fair value is near $1.44, reflecting this weak outlook. We see optional upside if product launches succeed.
Breaks if: Operating loss worsens beyond -$70 million in FY26
Breaks if: Loss of FDA approval or no new partnerships in 12 months
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity with a focus on advancing clinical programs and increasing product sales. The current thesis state is cautious, as recent financial performance has not kept pace with industry peers.
The market appears to be pricing in a significant expectations gap, suggesting that investors anticipate strong future growth despite the current loss-making status. Valuation is considered expensive compared to peers, reflecting a premium that may not be justified given the company's recent challenges.
Management has shown a commitment to increasing revenue through product sales, with consistent sequential growth in net product revenue. However, the overall financial performance has been neutral, and recent quality metrics have declined, indicating potential vulnerabilities.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Form strategic partnerships to enhance product development and market presence.
Breaks if: Revenue falls below $100 million in FY26
Continue growing net product revenue driven by ANKTIVA adoption and commercial execution in U.S. and global markets.
Stated as a priority in 3 of last 3 quarters. Net product revenue increased from $38.3 million in 2025-Q4 to $44.2 million in 2026-Q1 and further to $50.7 million in 2026-Q2, marking eight consecutive quarters of sequential growth. Full-year 2025 revenue was $113.0 million, a 700% increase over 2024. The trajectory is delivering consistent growth aligned with management's stated priority.
“Record Q2 2026 net product revenue of $50.7 million, up 92% year-over-year and 15% sequentially.”
“Q1 2026 net product revenue of approximately $44.2 million, representing ~168% year-over-year increase.”
“Full-year 2025 net product revenue of $113.0 million, a 700% increase over full-year 2024.”
The long-term thesis hinges on the ability of IBRX to secure strategic partnerships and advance its clinical programs successfully. Additionally, broader sector performance and macroeconomic factors, such as job growth, will play a crucial role in shaping investor sentiment.
Over the next 1 to 3 years, IBRX's trajectory will depend on its execution against management priorities and external market conditions. Not investment advice.